Trial Profile
Safety, Tolerability, and Pharmacokinetic Evaluation of Single Dose of a Novel Kappa Opioid Receptor Antagonist LY2456302 and Drug Interaction With Ethanol in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Aticaprant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- 19 Dec 2015 New trial record